| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to off-white | [Sequence]
DNA, d(P-thio)([2′-O-(2-methoxyethyl)]rG-[2′-O-(2-methoxyethyl)]rG-[2′-O-(2-methoxyethyl)]rG-[2′-O-(2-methoxyethyl)]rA-m5C-G-m5C-G-G-m5C-G-m5C-T-m5C-G-G-[2′-O-(2-methoxyethyl)]m5rU-[2′-O-(2-methoxyethyl)]m5rC-[2′-O-(2-methoxyethyl)]rA-[2′-O-(2-methoxyethyl)]m5rU) |
| Hazard Information | Back Directory | [Uses]
Apatorsen?is?an?antisense?oligonucleotide?designed?to?bind?to?Hsp27?mRNA,?resulting?in?the?inhibition of?the?production?of?Hsp27?protein. | [References]
[1] Spigel DR, Shipley DL, Waterhouse DM, et al. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. Oncologist. 2019;24(12):e1409-e1416. DOI:10.1634/theoncologist.2018-0518
[2] Yu EY, Ellard SL, Hotte SJ, et al. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 2018;36(2):278-287. DOI:10.1007/s10637-017-0553-x |
|
|